Provided by Tiger Trade Technology Pte. Ltd.

Dyne Therapeutics, Inc.

16.11
-0.1000-0.62%
Post-market: 16.110.00000.00%19:41 EDT
Volume:4.46M
Turnover:72.53M
Market Cap:3.01B
PE:-4.81
High:16.80
Open:16.05
Low:15.92
Close:16.21
52wk High:27.31
52wk Low:12.33
Shares:186.58M
Float Shares:186.00M
Volume Ratio:1.85
T/O Rate:2.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3486
EPS(LYR):-3.4740
ROE:-81.57%
ROA:-38.96%
PB:4.28
PE(LYR):-4.64

Loading ...

Dyne Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule

Reuters
·
Aug 21

Dyne Therapeutics Grants New-Hire Equity Awards for 212,500 Shares Under Inducement Plan

Reuters
·
Aug 21

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 21

Dyne Therapeutics Director Jason P. Rhodes Disposes of Common Shares Worth $67.45 Million

Reuters
·
Aug 18

Dyne Therapeutics (DYN) Gets FDA Clearance With Valuation Questions Back In Focus

Simply Wall St.
·
Aug 09

Sarepta Faces Competitive Pressures Despite Pipeline Updates, RBC Says

MT Newswires Live
·
Aug 07

Raymond James Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)

TIPRANKS
·
Aug 05

Dyne Therapeutics is Maintained at Outperform by RBC Capital

Dow Jones
·
Jul 31

RBC Raises Price Target on Dyne Therapeutics to $35 From $30, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jul 30

Anavex Life Sciences Q2 Net Loss Narrows on Lower R&D Costs

Reuters
·
Jul 30

Analysts Offer Insights on Healthcare Companies: Mach7 Technologies (OtherTDMMF) and Dyne Therapeutics (DYN)

TIPRANKS
·
Jul 30

Dyne Therapeutics, Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 30

Dyne Therapeutics Q2 EPS $(1.08) Misses $(0.75) Estimate

Benzinga Earnings
·
Jul 30

Dyne Therapeutics reports Q2 EPS ($1.08), consensus (75c)

TIPRANKS
·
Jul 30

Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

GlobeNewswire
·
Jul 30

Dyne Therapeutics Q2 Net Loss Widens 61.1% to $178.56 Million

Reuters
·
Jul 30

Dyne Therapeutics Director Dirk Kersten Disposes of 261,460 Common Shares Worth $6.67 Million

Reuters
·
Jul 30

Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Dyne Therapeutics (DYN)

TIPRANKS
·
Jul 29

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Centene (CNC) and Dyne Therapeutics (DYN)

TIPRANKS
·
Jul 29

Dyne Therapeutics receives FDA clearance to initiate DYNE-302 trial

TIPRANKS
·
Jul 28